Hot Flashes
Conditions
Keywords
prostate cancer, soy, androgen deprivation, quality of life, isoflavones
Brief summary
This study will look at the effects of a soy supplement called Revival on memory, quality of life, and hot flashes in men with prostate cancer who are being treated with testosterone suppression therapy. Hypothesis: Treating men who have prostate CA with daily Revival will result in at least a 50% reduction in hot flashes compared to placebo.
Detailed description
This research study will look at the effects of a soy supplement called Revival on memory, quality of life, and hot flashes in men with prostate cancer who are undergoing (ADT) androgen deprivation therapy. Participants will be given either placebo or Revival. Participants will be asked to take their supplement once/day for 14 weeks.Blood will be drawn to check on liver, kidney, thyroid, cholesterol,and prostate health. Urine will be collected to check on bone markers. Patients will be asked to complete questionnaires to test memory, attention span, and vocabulary.Possible benefits may include increase in memory, decrease in hot flashes, and a general increase in quality of life.
Interventions
Sponsors
Study design
Eligibility
Inclusion criteria
* men \> or =21 with prostate CA and hypogonadism for at least 3 months
Exclusion criteria
* on growth promoting agents * on appetite stimulating agents * on Prednisone and others
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cognitive Function as Assessed by the National Adult Reading Test (NART) | baseline, 6 weeks, 12 weeks | the NART estimates intelligence levels of English-speaking patients. It consists of 50 short words with irregular spelling or phonetic appearance which the participant must read and pronounce. The higher the score, the higher number of correct responses. Scores are 0-50. |
| Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Total Recall Score | baseline, 6 weeks, 12 weeks | The test consists 12 nouns, four words each from one of three semantic categories (e.g., precious gems, articles of clothing, vegetables, etc.), to be learned over the course of three learning trials. Approximately 20-25 min later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, & 6 semantically unrelated. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score ( -12) ; the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition. |
| Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Recognition Discrimination Index | baseline, 6 weeks, 12 weeks | The test consists 12 nouns, four words each from one of three semantic categories (e.g., precious gems, articles of clothing, vegetables, etc.), to be learned over the course of three learning trials. Approximately 20-25 min later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, & 6 semantically unrelated. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score ( -12) ; the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score= higher cognitive function. |
| Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Percent Retained | baseline, 6 weeks, 12 weeks | The test consists 12 nouns, four words each from one of three semantic categories (e.g., precious gems, articles of clothing, vegetables, etc.), to be learned over the course of three learning trials. Approximately 20-25 min later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, and 6 semantically unrelated. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score ( -12) ; the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives.A higher score= higher cognitive function. |
| Cognitive Function as Assessed by the F-A-S Test | baseline, 6 weeks, 12 weeks | The F-A-S Test, a subtest of the Neurosensory Center Comprehensive Examination for Aphasia (NCCEA), is a measure of phonemic word fluency, which is a type of verbal fluency. It assesses phonemic fluency by requesting an individual to orally produce as many words as possible that begin with the letters F, A, and S within a prescribed time frame (1 minute) |
| Cognition as Assessed by the Grooved Pegboard Test (GPT) , Dominant Hand Time (Seconds) | baseline, 6 weeks, 12 weeks | The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole. A faster time, indicates greater cognitive functioning. |
| Cognition as Assessed by the Grooved Pegboard Test (GPT) , Non-dominant Hand Time (Seconds) | baseline, 6 weeks, 12 weeks | The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the non-dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole. |
| Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Dominant Hand Drops | baseline, 6 weeks, 12 weeks | The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole. |
| Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Non- Dominant Hand Drops | baseline, 6 weeks, 12 weeks | The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole. |
| Cognition as Assessed by the Rex Complex Figure Test (RCFT), Immediate Recall | baseline, 6 weeks, 12 weeks | The test measures recognition memory for the elements of the Rey complex figure, and assesses the respondent's ability to use cues to retrieve information. Scoring of drawings is based on the widely used 36-point scoring system. Each of the 18 scoring units is scored based on accuracy and placement criteria. Items of the figure can earn points: 1. Correct Image: placed properly (2 points), placed poorly (1 point) 2. Distorted or Incomplete Image, but recognizable: placed properly (1 point), placed poorly (1/2) point 3. Absent or not recognizable: 0 points Scale ranges 0-36. with 36 being greatest cognitive function. |
| Cognition as Assessed by the Rex Complex Figure Test (RCFT), Delayed Recall | baseline, 6 weeks, 12 weeks | The test measures recognition memory for the elements of the Rey complex figure, and assesses the respondent's ability to use cues to retrieve information after 25-30 minutes. Scoring of drawings is based on the widely used 36-point scoring system. Each of the 18 scoring units is scored based on accuracy and placement criteria. Items of the figure can earn points: 1. Correct Image: placed properly (2 points), placed poorly (1 point) 2. Distorted or Incomplete Image, but recognizable: placed properly (1 point), placed poorly (1/2) point 3. Absent or not recognizable: 0 points Scale ranges 0-36, with 36 representing maximum cognition . |
| Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Total Score | baseline, 6 weeks, 12 weeks | The WSFQ contains 17 items that assess the domains of sexual desire/libido (6 items), arousal (1 item), orgasm/erectile function (7 items), and satisfaction(3 items). A five-point Likert-type scale ranging from always to never is used to generate a total score and four domain scores. The possible range of total sexual function scores is 17 to 85. Higher scores indicate better sexual function. |
| Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Libido | baseline, 6 weeks, 12 weeks | The domain of sexual desire/libido consists of 6 items. A five-point Likert-type scale ranging from always to never is used to generate a score, ranging from 6-30. Higher scores indicate increased libido/sexual desire. |
| Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Erectile Function | baseline, 6 weeks, 12 weeks | The domain of erectile function/orgasm consists of 7 items. A five-point Likert-type scale ranging from always to never is used to generate a score, ranging from 7-35. Higher scores indicate increased erectile function/achievement of orgasm. |
| Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Arousal | baseline, 6 weeks, 12 weeks | The domains of arousal (1 item subscale of the WSFQ), is assessed using a five-point Likert-type scale ranging from always to never to generate the score for arousal. The higher the number (range 1-5), the more the participant is able to experience arousal. |
| Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Sanctification | baseline, 6 weeks, 12 weeks | The domains of satisfaction (3 items), is assessed using a five-point Likert-type scale ranging from always to never to generate the score, ranging from 3-15. The higher the number, the higher the level of satisfaction with sexual function. |
| Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Total Score | baseline, 6 weeks, 12 weeks | IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions which refer to the past 4 weeks only. The questions are split into the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The total score ranges from 6-75 with 6 being minimal erectile function and 75 representing maximal erectile function. |
| Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Erectile Function | baseline, 6 weeks, 12 weeks | IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. Erectile function is one domain, making up 6 out of 15 questions. The score ranges from 1-30, with the lowest score representing minimal erectile function. |
| Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Intercourse Satisfaction | baseline, 6 weeks, 12 weeks | IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being satisfaction with intercourse. A score of 0-5 is awarded to each of the 3 questions which refer to the past 4 weeks only. The score rangers from 0-15, with a score of 0 indicating that no intercourse was attempted in the last 4 weeks, 1= almost or little to no sanctification, 15= very highly satisfied. |
| Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Orgasmic Function | baseline, 6 weeks, 12 weeks | IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being satisfaction with orgasm. A score of 0-5 is awarded to each of the 2 questions which refer to the past 4 weeks only. The score rangers from 1-10, with a score of 0 indicating that no sexual stimulation or intercourse was attempted in the last 4 weeks, 1= almost never or never ejaculated, 10= almost always or always |
| Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Sexual Desire | baseline, 6 weeks, 12 weeks | IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being sexual desire. A score of 0-5 is awarded to each of the 2 questions which refer to the past 4 weeks only. The score rangers from 2-10, with a score of 2 indicating very low or none at all, and 10 representing almost always/very high. |
| Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Overall Sexual Satisfaction | baseline, 6 weeks, 12 weeks | IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being sexual satisfaction. A score of 0-5 is awarded to each of the 2 questions which refer to the past 4 weeks only. The score rangers from 2-10, with a score of 2 indicating very dissatisfied and 10 being very satisfied. |
| Daytime Sleepiness as Assessed by Epworth Sleepiness Scale (ESS) | baseline, 6 weeks, 12 weeks | The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'. |
| Hot Flashes as Assessed by the Blatt-Kuppermann Index (Hot Flash Component) | baseline, 6 weeks, 12 weeks | Hot flashes were assessed using symptom severity 0= none, slight=1, moderate=2, and severe = 3. Hot flashes have a weighting factor of 4 on the overall Blatt-Kuppermann index, making score ranges 0-12, with 12 being the most severe hot flashes. |
| Mental Health as Assessed by the Short Form 36 Questionnaire | baseline, 6 weeks, 12 weeks | The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health |
| Physical Health as Assessed by the Short Form 36 Questionnaire | baseline, 6 weeks, 12 weeks | The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health |
| Fatigue as Assessed by the Short Form 36 Questionnaire | baseline, 6 weeks, 12 weeks | The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health |
| Physical Functioning as Assessed by the Short Form 36 Questionnaire | baseline, 6 weeks, 12 weeks | The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health |
| Body Pain as Assessed by the Short Form 36 Questionnaire | baseline, 6 weeks, 12 weeks | The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health |
| General Health Perceptions as Assessed by the Short Form 36 Questionnaire | baseline, 6 weeks, 12 weeks | The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health |
| Role Limitations Due to Physical Health as Assessed by the Short Form 36 Questionnaire | baseline, 6 weeks, 12 weeks | The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health |
| Role Limitations Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | baseline, 6 weeks, 12 weeks | The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health |
| Social Functioning Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | baseline, 6 weeks, 12 weeks | The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health |
Countries
United States
Participant flow
Pre-assignment details
39 participants were enrolled in this study. 3 were not randomized due to failed screening on laboratory assessment, 2 because they withdrew due to personal reasons, and 1 because of dislike of the taste of the compound.
Participants by arm
| Arm | Count |
|---|---|
| Isoflavone Isoflavone
Isoflavone | 17 |
| Placebo Placebos | 16 |
| Total | 33 |
Baseline characteristics
| Characteristic | Placebo | Total | Isoflavone |
|---|---|---|---|
| Age, Customized >= 21 years | 16 Participants | 33 Participants | 17 Participants |
| Region of Enrollment United States | 16 Participants | 33 Participants | 17 Participants |
| Sex: Female, Male Female | 0 Participants | 0 Participants | 0 Participants |
| Sex: Female, Male Male | 16 Participants | 33 Participants | 17 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 17 | 0 / 16 |
| other Total, other adverse events | 0 / 17 | 0 / 16 |
| serious Total, serious adverse events | 0 / 17 | 0 / 16 |
Outcome results
Body Pain as Assessed by the Short Form 36 Questionnaire
The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Body Pain as Assessed by the Short Form 36 Questionnaire | Baseline | 78 units on a scale | Standard Deviation 5.37 |
| Placebo | Body Pain as Assessed by the Short Form 36 Questionnaire | 6 weeks | 74.33 units on a scale | Standard Deviation 5.93 |
| Placebo | Body Pain as Assessed by the Short Form 36 Questionnaire | 12 weeks | 76.35 units on a scale | Standard Deviation 5.31 |
| Isoflavone | Body Pain as Assessed by the Short Form 36 Questionnaire | Baseline | 66 units on a scale | Standard Deviation 6.2 |
| Isoflavone | Body Pain as Assessed by the Short Form 36 Questionnaire | 6 weeks | 73 units on a scale | Standard Deviation 7.33 |
| Isoflavone | Body Pain as Assessed by the Short Form 36 Questionnaire | 12 weeks | 74 units on a scale | Standard Deviation 6.48 |
Cognition as Assessed by the Grooved Pegboard Test (GPT) , Dominant Hand Time (Seconds)
The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole. A faster time, indicates greater cognitive functioning.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Dominant Hand Time (Seconds) | Baseline | 101.5 time in seconds | Standard Deviation 8.14 |
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Dominant Hand Time (Seconds) | 6 weeks | 89.93 time in seconds | Standard Deviation 4.32 |
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Dominant Hand Time (Seconds) | 12 weeks | 90.75 time in seconds | Standard Deviation 6.05 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Dominant Hand Time (Seconds) | 6 weeks | 78.73 time in seconds | Standard Deviation 3.34 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Dominant Hand Time (Seconds) | 12 weeks | 83.8 time in seconds | Standard Deviation 5.72 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Dominant Hand Time (Seconds) | Baseline | 91.8 time in seconds | Standard Deviation 8.7 |
Cognition as Assessed by the Grooved Pegboard Test (GPT) , Non-dominant Hand Time (Seconds)
The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the non-dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Non-dominant Hand Time (Seconds) | 6 weeks | 98.86 time in seconds | Standard Deviation 7.76 |
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Non-dominant Hand Time (Seconds) | 12 weeks | 102.73 time in seconds | Standard Deviation 7.43 |
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Non-dominant Hand Time (Seconds) | Baseline | 115.43 time in seconds | Standard Deviation 9.75 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Non-dominant Hand Time (Seconds) | Baseline | 112.8 time in seconds | Standard Deviation 11.25 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Non-dominant Hand Time (Seconds) | 6 weeks | 89.2 time in seconds | Standard Deviation 3.05 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Non-dominant Hand Time (Seconds) | 12 weeks | 88.67 time in seconds | Standard Deviation 6.91 |
Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Dominant Hand Drops
The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Dominant Hand Drops | Baseline | 0.64 number of times peg dropped | Standard Deviation 0.27 |
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Dominant Hand Drops | 6 weeks | 0.14 number of times peg dropped | Standard Deviation 0.1 |
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Dominant Hand Drops | 12 weeks | 0.09 number of times peg dropped | Standard Deviation 0.09 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Dominant Hand Drops | Baseline | 0.4 number of times peg dropped | Standard Deviation 0.19 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Dominant Hand Drops | 6 weeks | 0.33 number of times peg dropped | Standard Deviation 0.21 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Dominant Hand Drops | 12 weeks | 0.2 number of times peg dropped | Standard Deviation 0.11 |
Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Non- Dominant Hand Drops
The GPT assesses eye-hand coordination and motor speed and thus requires sensory motor integration and a high level of motor processing. The test apparatus consists of a square metal surface (10.1 cm2) with a 5 × 5 matrix of keyhole shaped holes in various orientations. The task requires the examinee to pick up the keyhole shaped peg (3 mm in diameter) individually from the well just above the 5 × 5 matrix of holes from left to right and top to bottom as quickly as possible using the dominant hand. Because the holes are in various orientations, examinees must manipulate each peg in their hand (usually between the index finger and thumb) so that the peg aligns with the orientation of the hole.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Non- Dominant Hand Drops | Baseline | 0.21 number of times peg dropped | Standard Deviation 0.11 |
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Non- Dominant Hand Drops | 6 weeks | 0.07 number of times peg dropped | Standard Deviation 0.07 |
| Placebo | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Non- Dominant Hand Drops | 12 weeks | 0.45 number of times peg dropped | Standard Deviation 0.28 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Non- Dominant Hand Drops | Baseline | 0.6 number of times peg dropped | Standard Deviation 0.4 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Non- Dominant Hand Drops | 6 weeks | 0.4 number of times peg dropped | Standard Deviation 0.13 |
| Isoflavone | Cognition as Assessed by the Grooved Pegboard Test (GPT) , Number of Non- Dominant Hand Drops | 12 weeks | 0.27 number of times peg dropped | Standard Deviation 0.12 |
Cognition as Assessed by the Rex Complex Figure Test (RCFT), Delayed Recall
The test measures recognition memory for the elements of the Rey complex figure, and assesses the respondent's ability to use cues to retrieve information after 25-30 minutes. Scoring of drawings is based on the widely used 36-point scoring system. Each of the 18 scoring units is scored based on accuracy and placement criteria. Items of the figure can earn points: 1. Correct Image: placed properly (2 points), placed poorly (1 point) 2. Distorted or Incomplete Image, but recognizable: placed properly (1 point), placed poorly (1/2) point 3. Absent or not recognizable: 0 points Scale ranges 0-36, with 36 representing maximum cognition .
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Delayed Recall | Baseline | 20.37 units on a scale | Standard Deviation 1.44 |
| Placebo | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Delayed Recall | 6 weeks | 23.07 units on a scale | Standard Deviation 1.43 |
| Placebo | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Delayed Recall | 12 weeks | 24.42 units on a scale | Standard Deviation 1.79 |
| Isoflavone | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Delayed Recall | Baseline | 23.07 units on a scale | Standard Deviation 1.43 |
| Isoflavone | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Delayed Recall | 6 weeks | 20.43 units on a scale | Standard Deviation 1.61 |
| Isoflavone | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Delayed Recall | 12 weeks | 24.27 units on a scale | Standard Deviation 2.04 |
Cognition as Assessed by the Rex Complex Figure Test (RCFT), Immediate Recall
The test measures recognition memory for the elements of the Rey complex figure, and assesses the respondent's ability to use cues to retrieve information. Scoring of drawings is based on the widely used 36-point scoring system. Each of the 18 scoring units is scored based on accuracy and placement criteria. Items of the figure can earn points: 1. Correct Image: placed properly (2 points), placed poorly (1 point) 2. Distorted or Incomplete Image, but recognizable: placed properly (1 point), placed poorly (1/2) point 3. Absent or not recognizable: 0 points Scale ranges 0-36. with 36 being greatest cognitive function.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Immediate Recall | Baseline | 20.87 units on a scale | Standard Deviation 1.15 |
| Placebo | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Immediate Recall | 6 weeks | 24.33 units on a scale | Standard Deviation 1.4 |
| Placebo | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Immediate Recall | 12 weeks | 25.92 units on a scale | Standard Deviation 1.52 |
| Isoflavone | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Immediate Recall | Baseline | 16.03 units on a scale | Standard Deviation 2.21 |
| Isoflavone | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Immediate Recall | 6 weeks | 22.33 units on a scale | Standard Deviation 1.62 |
| Isoflavone | Cognition as Assessed by the Rex Complex Figure Test (RCFT), Immediate Recall | 12 weeks | 25.13 units on a scale | Standard Deviation 1.91 |
Cognitive Function as Assessed by the F-A-S Test
The F-A-S Test, a subtest of the Neurosensory Center Comprehensive Examination for Aphasia (NCCEA), is a measure of phonemic word fluency, which is a type of verbal fluency. It assesses phonemic fluency by requesting an individual to orally produce as many words as possible that begin with the letters F, A, and S within a prescribed time frame (1 minute)
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognitive Function as Assessed by the F-A-S Test | Baseline | 58.79 seconds | Standard Deviation 3.65 |
| Placebo | Cognitive Function as Assessed by the F-A-S Test | 6 weeks | 64.47 seconds | Standard Deviation 4.51 |
| Placebo | Cognitive Function as Assessed by the F-A-S Test | 12 weeks | 63.31 seconds | Standard Deviation 4.43 |
| Isoflavone | Cognitive Function as Assessed by the F-A-S Test | Baseline | 55.36 seconds | Standard Deviation 5.08 |
| Isoflavone | Cognitive Function as Assessed by the F-A-S Test | 6 weeks | 56.93 seconds | Standard Deviation 4.78 |
| Isoflavone | Cognitive Function as Assessed by the F-A-S Test | 12 weeks | 57.93 seconds | Standard Deviation 4.42 |
Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Percent Retained
The test consists 12 nouns, four words each from one of three semantic categories (e.g., precious gems, articles of clothing, vegetables, etc.), to be learned over the course of three learning trials. Approximately 20-25 min later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, and 6 semantically unrelated. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score ( -12) ; the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives.A higher score= higher cognitive function.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Percent Retained | Baseline | 100.88 units on a scale | Standard Deviation 5.98 |
| Placebo | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Percent Retained | 6 weeks | 94.31 units on a scale | Standard Deviation 2.38 |
| Placebo | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Percent Retained | 12 weeks | 94.68 units on a scale | Standard Deviation 3.63 |
| Isoflavone | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Percent Retained | 6 weeks | 94.08 units on a scale | Standard Deviation 4.3 |
| Isoflavone | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Percent Retained | 12 weeks | 95.21 units on a scale | Standard Deviation 5.5 |
| Isoflavone | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Percent Retained | Baseline | 89.82 units on a scale | Standard Deviation 5.84 |
Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Recognition Discrimination Index
The test consists 12 nouns, four words each from one of three semantic categories (e.g., precious gems, articles of clothing, vegetables, etc.), to be learned over the course of three learning trials. Approximately 20-25 min later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, & 6 semantically unrelated. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score ( -12) ; the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score= higher cognitive function.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Recognition Discrimination Index | Baseline | 22.13 units on a scale | Standard Deviation 0.46 |
| Placebo | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Recognition Discrimination Index | 6 weeks | 20.4 units on a scale | Standard Deviation 1 |
| Placebo | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Recognition Discrimination Index | 12 weeks | 22.77 units on a scale | Standard Deviation 0.53 |
| Isoflavone | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Recognition Discrimination Index | Baseline | 20.8 units on a scale | Standard Deviation 0.87 |
| Isoflavone | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Recognition Discrimination Index | 6 weeks | 21.47 units on a scale | Standard Deviation 1 |
| Isoflavone | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Recognition Discrimination Index | 12 weeks | 22.67 units on a scale | Standard Deviation 0.67 |
Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Total Recall Score
The test consists 12 nouns, four words each from one of three semantic categories (e.g., precious gems, articles of clothing, vegetables, etc.), to be learned over the course of three learning trials. Approximately 20-25 min later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives, 6 semantically related, & 6 semantically unrelated. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score ( -12) ; the retention (%) score (0-100%) is calculated by dividing the delayed recall trial by the higher of learning trial 2 or 3; and the recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher score = higher cognition.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Total Recall Score | Baseline | 24.67 units on a scale | Standard Deviation 1.67 |
| Placebo | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Total Recall Score | 6 weeks | 24.87 units on a scale | Standard Deviation 1.57 |
| Placebo | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Total Recall Score | 12 weeks | 25.85 units on a scale | Standard Deviation 1.56 |
| Isoflavone | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Total Recall Score | Baseline | 21.6 units on a scale | Standard Deviation 1.26 |
| Isoflavone | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Total Recall Score | 6 weeks | 22.53 units on a scale | Standard Deviation 0.96 |
| Isoflavone | Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Total Recall Score | 12 weeks | 22.47 units on a scale | Standard Deviation 1.39 |
Cognitive Function as Assessed by the National Adult Reading Test (NART)
the NART estimates intelligence levels of English-speaking patients. It consists of 50 short words with irregular spelling or phonetic appearance which the participant must read and pronounce. The higher the score, the higher number of correct responses. Scores are 0-50.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Cognitive Function as Assessed by the National Adult Reading Test (NART) | Baseline | 45.2 units on a scale | Standard Deviation 2.12 |
| Placebo | Cognitive Function as Assessed by the National Adult Reading Test (NART) | 6 weeks | 42.43 units on a scale | Standard Deviation 2.66 |
| Placebo | Cognitive Function as Assessed by the National Adult Reading Test (NART) | 12 weeks | 43.69 units on a scale | Standard Deviation 2.83 |
| Isoflavone | Cognitive Function as Assessed by the National Adult Reading Test (NART) | Baseline | 39.6 units on a scale | Standard Deviation 3.02 |
| Isoflavone | Cognitive Function as Assessed by the National Adult Reading Test (NART) | 6 weeks | 41.29 units on a scale | Standard Deviation 3.25 |
| Isoflavone | Cognitive Function as Assessed by the National Adult Reading Test (NART) | 12 weeks | 41.57 units on a scale | Standard Deviation 3.21 |
Daytime Sleepiness as Assessed by Epworth Sleepiness Scale (ESS)
The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. Most people engage in those activities at least occasionally, although not necessarily every day. The ESS score (the sum of 8 item scores, 0-3) can range from 0 to 24. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Daytime Sleepiness as Assessed by Epworth Sleepiness Scale (ESS) | Baseline | 7.07 units on a scale | Standard Deviation 0.928 |
| Placebo | Daytime Sleepiness as Assessed by Epworth Sleepiness Scale (ESS) | 6 weeks | 7.2 units on a scale | Standard Deviation 0.634 |
| Placebo | Daytime Sleepiness as Assessed by Epworth Sleepiness Scale (ESS) | 12 weeks | 7.31 units on a scale | Standard Deviation 1.195 |
| Isoflavone | Daytime Sleepiness as Assessed by Epworth Sleepiness Scale (ESS) | Baseline | 8.2 units on a scale | Standard Deviation 1.284 |
| Isoflavone | Daytime Sleepiness as Assessed by Epworth Sleepiness Scale (ESS) | 6 weeks | 7.2 units on a scale | Standard Deviation 1.36 |
| Isoflavone | Daytime Sleepiness as Assessed by Epworth Sleepiness Scale (ESS) | 12 weeks | 7.4 units on a scale | Standard Deviation 1.05 |
Fatigue as Assessed by the Short Form 36 Questionnaire
The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Fatigue as Assessed by the Short Form 36 Questionnaire | Baseline | 64 units on a scale | Standard Deviation 5.65 |
| Placebo | Fatigue as Assessed by the Short Form 36 Questionnaire | 6 weeks | 63.67 units on a scale | Standard Deviation 4.1 |
| Placebo | Fatigue as Assessed by the Short Form 36 Questionnaire | 12 weeks | 67.69 units on a scale | Standard Deviation 4.62 |
| Isoflavone | Fatigue as Assessed by the Short Form 36 Questionnaire | Baseline | 50.67 units on a scale | Standard Deviation 8.24 |
| Isoflavone | Fatigue as Assessed by the Short Form 36 Questionnaire | 6 weeks | 49.67 units on a scale | Standard Deviation 7.28 |
| Isoflavone | Fatigue as Assessed by the Short Form 36 Questionnaire | 12 weeks | 54 units on a scale | Standard Deviation 5.88 |
General Health Perceptions as Assessed by the Short Form 36 Questionnaire
The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | General Health Perceptions as Assessed by the Short Form 36 Questionnaire | Baseline | 63.37 units on a scale | Standard Deviation 5.24 |
| Placebo | General Health Perceptions as Assessed by the Short Form 36 Questionnaire | 6 weeks | 65.67 units on a scale | Standard Deviation 4.57 |
| Placebo | General Health Perceptions as Assessed by the Short Form 36 Questionnaire | 12 weeks | 61.54 units on a scale | Standard Deviation 5.2 |
| Isoflavone | General Health Perceptions as Assessed by the Short Form 36 Questionnaire | Baseline | 56 units on a scale | Standard Deviation 3.94 |
| Isoflavone | General Health Perceptions as Assessed by the Short Form 36 Questionnaire | 6 weeks | 57 units on a scale | Standard Deviation 6.15 |
| Isoflavone | General Health Perceptions as Assessed by the Short Form 36 Questionnaire | 12 weeks | 58.67 units on a scale | Standard Deviation 4.77 |
Hot Flashes as Assessed by the Blatt-Kuppermann Index (Hot Flash Component)
Hot flashes were assessed using symptom severity 0= none, slight=1, moderate=2, and severe = 3. Hot flashes have a weighting factor of 4 on the overall Blatt-Kuppermann index, making score ranges 0-12, with 12 being the most severe hot flashes.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Hot Flashes as Assessed by the Blatt-Kuppermann Index (Hot Flash Component) | Baseline | 4.53 units on a scale | Standard Deviation 0.729 |
| Placebo | Hot Flashes as Assessed by the Blatt-Kuppermann Index (Hot Flash Component) | 6 weeks | 5 units on a scale | Standard Deviation 1.013 |
| Placebo | Hot Flashes as Assessed by the Blatt-Kuppermann Index (Hot Flash Component) | 12 weeks | 4.38 units on a scale | Standard Deviation 0.903 |
| Isoflavone | Hot Flashes as Assessed by the Blatt-Kuppermann Index (Hot Flash Component) | Baseline | 7 units on a scale | Standard Deviation 0.941 |
| Isoflavone | Hot Flashes as Assessed by the Blatt-Kuppermann Index (Hot Flash Component) | 6 weeks | 6.43 units on a scale | Standard Deviation 1.212 |
| Isoflavone | Hot Flashes as Assessed by the Blatt-Kuppermann Index (Hot Flash Component) | 12 weeks | 7 units on a scale | Standard Deviation 0.845 |
Mental Health as Assessed by the Short Form 36 Questionnaire
The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Mental Health as Assessed by the Short Form 36 Questionnaire | Baseline | 81.23 units on a scale | Standard Deviation 4.62 |
| Placebo | Mental Health as Assessed by the Short Form 36 Questionnaire | 6 weeks | 77.37 units on a scale | Standard Deviation 4.64 |
| Placebo | Mental Health as Assessed by the Short Form 36 Questionnaire | 12 weeks | 80.66 units on a scale | Standard Deviation 4.87 |
| Isoflavone | Mental Health as Assessed by the Short Form 36 Questionnaire | Baseline | 69.67 units on a scale | Standard Deviation 7.16 |
| Isoflavone | Mental Health as Assessed by the Short Form 36 Questionnaire | 6 weeks | 71.36 units on a scale | Standard Deviation 5.62 |
| Isoflavone | Mental Health as Assessed by the Short Form 36 Questionnaire | 12 weeks | 77.18 units on a scale | Standard Deviation 4.02 |
Physical Functioning as Assessed by the Short Form 36 Questionnaire
The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Physical Functioning as Assessed by the Short Form 36 Questionnaire | 12 weeks | 84.23 units on a scale | Standard Deviation 3.34 |
| Placebo | Physical Functioning as Assessed by the Short Form 36 Questionnaire | Baseline | 83.33 units on a scale | Standard Deviation 5.53 |
| Placebo | Physical Functioning as Assessed by the Short Form 36 Questionnaire | 6 weeks | 82.14 units on a scale | Standard Deviation 4.41 |
| Isoflavone | Physical Functioning as Assessed by the Short Form 36 Questionnaire | 6 weeks | 71.33 units on a scale | Standard Deviation 6.96 |
| Isoflavone | Physical Functioning as Assessed by the Short Form 36 Questionnaire | Baseline | 71.67 units on a scale | Standard Deviation 9.41 |
| Isoflavone | Physical Functioning as Assessed by the Short Form 36 Questionnaire | 12 weeks | 78.33 units on a scale | Standard Deviation 8.07 |
Physical Health as Assessed by the Short Form 36 Questionnaire
The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Physical Health as Assessed by the Short Form 36 Questionnaire | Baseline | 76.25 units on a scale | Standard Deviation 5.59 |
| Placebo | Physical Health as Assessed by the Short Form 36 Questionnaire | 6 weeks | 74.73 units on a scale | Standard Deviation 4.38 |
| Placebo | Physical Health as Assessed by the Short Form 36 Questionnaire | 12 weeks | 72.36 units on a scale | Standard Deviation 5.45 |
| Isoflavone | Physical Health as Assessed by the Short Form 36 Questionnaire | Baseline | 64.25 units on a scale | Standard Deviation 6.17 |
| Isoflavone | Physical Health as Assessed by the Short Form 36 Questionnaire | 6 weeks | 65.75 units on a scale | Standard Deviation 6.56 |
| Isoflavone | Physical Health as Assessed by the Short Form 36 Questionnaire | 12 weeks | 66.92 units on a scale | Standard Deviation 5.63 |
Role Limitations Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire
The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Role Limitations Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | Baseline | 82.22 units on a scale | Standard Deviation 9.12 |
| Placebo | Role Limitations Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | 6 weeks | 75.56 units on a scale | Standard Deviation 10.01 |
| Placebo | Role Limitations Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | 12 weeks | 76.92 units on a scale | Standard Deviation 10.93 |
| Isoflavone | Role Limitations Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | Baseline | 68.89 units on a scale | Standard Deviation 11.02 |
| Isoflavone | Role Limitations Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | 6 weeks | 75.56 units on a scale | Standard Deviation 8.27 |
| Isoflavone | Role Limitations Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | 12 weeks | 80 units on a scale | Standard Deviation 7.83 |
Role Limitations Due to Physical Health as Assessed by the Short Form 36 Questionnaire
The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Role Limitations Due to Physical Health as Assessed by the Short Form 36 Questionnaire | Baseline | 80 units on a scale | Standard Deviation 9.82 |
| Placebo | Role Limitations Due to Physical Health as Assessed by the Short Form 36 Questionnaire | 6 weeks | 71.67 units on a scale | Standard Deviation 9.41 |
| Placebo | Role Limitations Due to Physical Health as Assessed by the Short Form 36 Questionnaire | 12 weeks | 67.31 units on a scale | Standard Deviation 12.46 |
| Isoflavone | Role Limitations Due to Physical Health as Assessed by the Short Form 36 Questionnaire | Baseline | 63.33 units on a scale | Standard Deviation 11.67 |
| Isoflavone | Role Limitations Due to Physical Health as Assessed by the Short Form 36 Questionnaire | 6 weeks | 61.67 units on a scale | Standard Deviation 11.41 |
| Isoflavone | Role Limitations Due to Physical Health as Assessed by the Short Form 36 Questionnaire | 12 weeks | 56.67 units on a scale | Standard Deviation 10.76 |
Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Erectile Function
IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. Erectile function is one domain, making up 6 out of 15 questions. The score ranges from 1-30, with the lowest score representing minimal erectile function.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Erectile Function | Baseline | 7.33 units on a scale | Standard Deviation 2.44 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Erectile Function | 6 weeks | 5.87 units on a scale | Standard Deviation 2.35 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Erectile Function | 12 weeks | 5.85 units on a scale | Standard Deviation 2.44 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Erectile Function | Baseline | 3.27 units on a scale | Standard Deviation 1.07 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Erectile Function | 6 weeks | 3.67 units on a scale | Standard Deviation 1.06 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Erectile Function | 12 weeks | 4.53 units on a scale | Standard Deviation 1.55 |
Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Intercourse Satisfaction
IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being satisfaction with intercourse. A score of 0-5 is awarded to each of the 3 questions which refer to the past 4 weeks only. The score rangers from 0-15, with a score of 0 indicating that no intercourse was attempted in the last 4 weeks, 1= almost or little to no sanctification, 15= very highly satisfied.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Intercourse Satisfaction | Baseline | 3.8 units on a scale | Standard Deviation 1.35 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Intercourse Satisfaction | 6 weeks | 2.33 units on a scale | Standard Deviation 1.11 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Intercourse Satisfaction | 12 weeks | 2.15 units on a scale | Standard Deviation 1.25 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Intercourse Satisfaction | 6 weeks | 1.2 units on a scale | Standard Deviation 0.59 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Intercourse Satisfaction | Baseline | 0.67 units on a scale | Standard Deviation 0.46 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Intercourse Satisfaction | 12 weeks | 1.53 units on a scale | Standard Deviation 0.74 |
Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Orgasmic Function
IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being satisfaction with orgasm. A score of 0-5 is awarded to each of the 2 questions which refer to the past 4 weeks only. The score rangers from 1-10, with a score of 0 indicating that no sexual stimulation or intercourse was attempted in the last 4 weeks, 1= almost never or never ejaculated, 10= almost always or always
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Orgasmic Function | Baseline | 1.73 units on a scale | Standard Deviation 0.62 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Orgasmic Function | 6 weeks | 1.27 units on a scale | Standard Deviation 0.54 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Orgasmic Function | 12 weeks | 1.46 units on a scale | Standard Deviation 0.87 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Orgasmic Function | 6 weeks | 1.07 units on a scale | Standard Deviation 0.5 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Orgasmic Function | Baseline | 0.47 units on a scale | Standard Deviation 0.26 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Orgasmic Function | 12 weeks | 1.13 units on a scale | Standard Deviation 0.47 |
Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Overall Sexual Satisfaction
IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being sexual satisfaction. A score of 0-5 is awarded to each of the 2 questions which refer to the past 4 weeks only. The score rangers from 2-10, with a score of 2 indicating very dissatisfied and 10 being very satisfied.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Overall Sexual Satisfaction | Baseline | 4.73 units on a scale | Standard Deviation 0.73 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Overall Sexual Satisfaction | 6 weeks | 4.47 units on a scale | Standard Deviation 0.72 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Overall Sexual Satisfaction | 12 weeks | 4.08 units on a scale | Standard Deviation 0.61 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Overall Sexual Satisfaction | Baseline | 3.85 units on a scale | Standard Deviation 0.66 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Overall Sexual Satisfaction | 6 weeks | 4.2 units on a scale | Standard Deviation 0.63 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Overall Sexual Satisfaction | 12 weeks | 4.64 units on a scale | Standard Deviation 0.86 |
Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Sexual Desire
IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials, one domain being sexual desire. A score of 0-5 is awarded to each of the 2 questions which refer to the past 4 weeks only. The score rangers from 2-10, with a score of 2 indicating very low or none at all, and 10 representing almost always/very high.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Sexual Desire | Baseline | 3.73 units on a scale | Standard Deviation 0.6 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Sexual Desire | 6 weeks | 3.47 units on a scale | Standard Deviation 0.52 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Sexual Desire | 12 weeks | 3.54 units on a scale | Standard Deviation 0.57 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Sexual Desire | 6 weeks | 3.07 units on a scale | Standard Deviation 0.33 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Sexual Desire | Baseline | 2.8 units on a scale | Standard Deviation 0.26 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Sexual Desire | 12 weeks | 2.93 units on a scale | Standard Deviation 0.34 |
Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Total Score
IIEF Questionnaire is used for the clinical assessment of erectile dysfunction and treatment outcomes in clinical trials. A score of 0-5 is awarded to each of the 15 questions which refer to the past 4 weeks only. The questions are split into the 4 main domains of male sexual function: erectile function, orgasmic function, sexual desire and intercourse satisfaction. The total score ranges from 6-75 with 6 being minimal erectile function and 75 representing maximal erectile function.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Total Score | 12 weeks | 17.08 units on a scale | Standard Deviation 5 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Total Score | Baseline | 21.33 units on a scale | Standard Deviation 5.17 |
| Placebo | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Total Score | 6 weeks | 17.4 units on a scale | Standard Deviation 4.6 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Total Score | Baseline | 11.31 units on a scale | Standard Deviation 2.1 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Total Score | 6 weeks | 13.2 units on a scale | Standard Deviation 2.24 |
| Isoflavone | Sexual Function as Assessed by the International Index of Erectile Function (IIEF) Questionnaire, Total Score | 12 weeks | 15 units on a scale | Standard Deviation 3.29 |
Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Arousal
The domains of arousal (1 item subscale of the WSFQ), is assessed using a five-point Likert-type scale ranging from always to never to generate the score for arousal. The higher the number (range 1-5), the more the participant is able to experience arousal.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Arousal | Baseline | 3.92 units on a scale | Standard Deviation 0.33 |
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Arousal | 6 weeks | 4.36 units on a scale | Standard Deviation 0.23 |
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Arousal | 12 weeks | 3.45 units on a scale | Standard Deviation 0.51 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Arousal | Baseline | 3.79 units on a scale | Standard Deviation 0.37 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Arousal | 6 weeks | 4.13 units on a scale | Standard Deviation 0.27 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Arousal | 12 weeks | 4.31 units on a scale | Standard Deviation 0.31 |
Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Erectile Function
The domain of erectile function/orgasm consists of 7 items. A five-point Likert-type scale ranging from always to never is used to generate a score, ranging from 7-35. Higher scores indicate increased erectile function/achievement of orgasm.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Erectile Function | Baseline | 26.83 units on a scale | Standard Deviation 1.35 |
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Erectile Function | 6 weeks | 26.29 units on a scale | Standard Deviation 1.14 |
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Erectile Function | 12 weeks | 25.36 units on a scale | Standard Deviation 1.65 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Erectile Function | Baseline | 26 units on a scale | Standard Deviation 1.24 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Erectile Function | 6 weeks | 25.92 units on a scale | Standard Deviation 1.44 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Erectile Function | 12 weeks | 27.46 units on a scale | Standard Deviation 1.5 |
Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Libido
The domain of sexual desire/libido consists of 6 items. A five-point Likert-type scale ranging from always to never is used to generate a score, ranging from 6-30. Higher scores indicate increased libido/sexual desire.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Libido | Baseline | 22.21 units on a scale | Standard Deviation 1.19 |
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Libido | 6 weeks | 22.13 units on a scale | Standard Deviation 1.15 |
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Libido | 12 weeks | 21.42 units on a scale | Standard Deviation 1.28 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Libido | Baseline | 21.4 units on a scale | Standard Deviation 1.4 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Libido | 6 weeks | 21.36 units on a scale | Standard Deviation 1.2 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Libido | 12 weeks | 22.93 units on a scale | Standard Deviation 1.3 |
Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Sanctification
The domains of satisfaction (3 items), is assessed using a five-point Likert-type scale ranging from always to never to generate the score, ranging from 3-15. The higher the number, the higher the level of satisfaction with sexual function.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Sanctification | 6 weeks | 11 units on a scale | Standard Deviation 0.71 |
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Sanctification | Baseline | 10.92 units on a scale | Standard Deviation 0.77 |
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Sanctification | 12 weeks | 11.75 units on a scale | Standard Deviation 0.68 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Sanctification | Baseline | 10.69 units on a scale | Standard Deviation 0.71 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Sanctification | 6 weeks | 11.92 units on a scale | Standard Deviation 0.81 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Sanctification | 12 weeks | 12.5 units on a scale | Standard Deviation 0.69 |
Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Total Score
The WSFQ contains 17 items that assess the domains of sexual desire/libido (6 items), arousal (1 item), orgasm/erectile function (7 items), and satisfaction(3 items). A five-point Likert-type scale ranging from always to never is used to generate a total score and four domain scores. The possible range of total sexual function scores is 17 to 85. Higher scores indicate better sexual function.
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Total Score | Baseline | 62.92 units on a scale | Standard Deviation 3.18 |
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Total Score | 6 weeks | 63.21 units on a scale | Standard Deviation 2.3 |
| Placebo | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Total Score | 12 weeks | 59.7 units on a scale | Standard Deviation 3.39 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Total Score | Baseline | 62 units on a scale | Standard Deviation 3.71 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Total Score | 6 weeks | 63.83 units on a scale | Standard Deviation 2.79 |
| Isoflavone | Sexual Function as Assessed by the Watts Sexual Function Questionnaire (WSFQ), Total Score | 12 weeks | 67 units on a scale | Standard Deviation 3.68 |
Social Functioning Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire
The SF-36 has eight scaled scores; the scores are weighted sums of the questions in each section. Scores range from 0 - 100 Lower scores = more disability, higher scores = less disability Sections: Vitality, Physical functioning, Bodily pain, General health perception, Physical role functioning, Emotional role functioning, Social role functioning, Mental health
Time frame: baseline, 6 weeks, 12 weeks
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Social Functioning Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | Baseline | 94.17 units on a scale | Standard Deviation 4.2 |
| Placebo | Social Functioning Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | 6 weeks | 83.33 units on a scale | Standard Deviation 6.06 |
| Placebo | Social Functioning Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | 12 weeks | 89.42 units on a scale | Standard Deviation 3.7 |
| Isoflavone | Social Functioning Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | Baseline | 78.33 units on a scale | Standard Deviation 9 |
| Isoflavone | Social Functioning Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | 6 weeks | 78.33 units on a scale | Standard Deviation 8.75 |
| Isoflavone | Social Functioning Due to Emotional Role Functioning as Assessed by the Short Form 36 Questionnaire | 12 weeks | 88.33 units on a scale | Standard Deviation 5.38 |